The Middle East nuclear medicine market size was estimated at USD 375.4 Million in 2025 and is projected to reach USD 727.3 million by 2033, growing at a CAGR of 8.62% from 2025 to 2033. The market is driven by increasing healthcare infrastructure investments and the rising demand for advanced diagnostic and therapeutic options.
The industry is witnessing significant growth due to advancements in both diagnostic and therapeutic applications, coupled with strategic government investments in healthcare infrastructure. Nuclear medicine plays a vital role in the region’s healthcare transformation, especially as governments recognize its potential for early disease detection and precision-based treatment., for example, the UAE is investing heavily in nuclear medicine technologies as part of its Vision 2030 initiative. According to the UAE Ministry of Health and Prevention’s Statistical Annual Report of 2023, the government’s health policy includes expanding nuclear medicine centers and providing state-of-the-art cancer treatment services across the nation. The report also highlights that there is an ongoing emphasis on enhancing diagnostic capabilities with cutting-edge technologies, including PET and SPECT scanners.
A significant driver of this market growth is the increasing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, which are putting pressure on healthcare systems to adopt advanced diagnostic and treatment modalities. A Gulf News article published on August 9, 2024, reported that Saudi Arabia has approximately 22,000 new cancer cases, with Riyadh leading the kingdom in cancer cases. Of these, about 17,941 are Saudi nationals, and 4,215 are non-Saudis. Breast cancer is the most prevalent type, with about 3,500 cases recorded. Other common cancers include colon cancer (2,200 cases), lymphoma (1,400 cases), and thyroid cancer (600 cases). This alarming increase in cancer cases has created a pressing need for more specialized healthcare services, including nuclear medicine for early diagnosis and effective treatment. Techniques such as PET and SPECT are becoming integral to oncology protocols, helping doctors detect and assess cancers at early stages. With this rising demand, Saudi Arabia has begun integrating advanced nuclear medicine technologies in several hospitals, including the King Faisal Specialist Hospital in Riyadh, which has recently upgraded its nuclear imaging services to handle the increasing patient load. For instance, The fifth annual UAE International Nuclear Medicine Conference, held in April 2025, highlighted the country's advancements in nuclear medicine. Experts reported successful treatments of prostate and endocrine tumors using targeted radiotherapy, with a 100% tumor control rate in 15 cases. The conference also noted that the UAE operates 14 specialized nuclear medicine centers across various emirates, supported by the latest devices and technologies, positioning the country as a regional leader in this specialty.
In addition to diagnostic advances, nuclear medicine’s therapeutic applications are expanding rapidly across the region. One notable development is the collaboration between the International Atomic Energy Agency (IAEA) and the UAE, which aims to boost the production of radiopharmaceuticals locally. This collaboration, as outlined in a 2024 IAEA report, is focused on improving the UAE’s capacity to produce radiopharmaceuticals for cancer treatment, which will reduce the country’s reliance on imports, also make critical therapies more accessible to underserved populations. This initiative is part of a broader regional strategy to develop self-sufficiency in radiopharmaceuticals, thus lowering costs and ensuring more consistent availability of treatment.
Furthermore, Jordan has positioned itself as a leader in nuclear research with its Jordan Research and Training Reactor (JRTR), which has been operational since 2016. This reactor plays a crucial role in producing medical isotopes used in diagnostic and therapeutic nuclear medicine. The JRTR not only strengthens Jordan’s domestic capabilities but also positions the country as a key player in the regional nuclear medicine landscape, exporting isotopes to other Middle Eastern countries. This development underscores the growing importance of nuclear medicine in the region and the ongoing efforts to enhance access to advanced healthcare solutions.
This product will be delivered within 2 business days.
The industry is witnessing significant growth due to advancements in both diagnostic and therapeutic applications, coupled with strategic government investments in healthcare infrastructure. Nuclear medicine plays a vital role in the region’s healthcare transformation, especially as governments recognize its potential for early disease detection and precision-based treatment., for example, the UAE is investing heavily in nuclear medicine technologies as part of its Vision 2030 initiative. According to the UAE Ministry of Health and Prevention’s Statistical Annual Report of 2023, the government’s health policy includes expanding nuclear medicine centers and providing state-of-the-art cancer treatment services across the nation. The report also highlights that there is an ongoing emphasis on enhancing diagnostic capabilities with cutting-edge technologies, including PET and SPECT scanners.
A significant driver of this market growth is the increasing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, which are putting pressure on healthcare systems to adopt advanced diagnostic and treatment modalities. A Gulf News article published on August 9, 2024, reported that Saudi Arabia has approximately 22,000 new cancer cases, with Riyadh leading the kingdom in cancer cases. Of these, about 17,941 are Saudi nationals, and 4,215 are non-Saudis. Breast cancer is the most prevalent type, with about 3,500 cases recorded. Other common cancers include colon cancer (2,200 cases), lymphoma (1,400 cases), and thyroid cancer (600 cases). This alarming increase in cancer cases has created a pressing need for more specialized healthcare services, including nuclear medicine for early diagnosis and effective treatment. Techniques such as PET and SPECT are becoming integral to oncology protocols, helping doctors detect and assess cancers at early stages. With this rising demand, Saudi Arabia has begun integrating advanced nuclear medicine technologies in several hospitals, including the King Faisal Specialist Hospital in Riyadh, which has recently upgraded its nuclear imaging services to handle the increasing patient load. For instance, The fifth annual UAE International Nuclear Medicine Conference, held in April 2025, highlighted the country's advancements in nuclear medicine. Experts reported successful treatments of prostate and endocrine tumors using targeted radiotherapy, with a 100% tumor control rate in 15 cases. The conference also noted that the UAE operates 14 specialized nuclear medicine centers across various emirates, supported by the latest devices and technologies, positioning the country as a regional leader in this specialty.
In addition to diagnostic advances, nuclear medicine’s therapeutic applications are expanding rapidly across the region. One notable development is the collaboration between the International Atomic Energy Agency (IAEA) and the UAE, which aims to boost the production of radiopharmaceuticals locally. This collaboration, as outlined in a 2024 IAEA report, is focused on improving the UAE’s capacity to produce radiopharmaceuticals for cancer treatment, which will reduce the country’s reliance on imports, also make critical therapies more accessible to underserved populations. This initiative is part of a broader regional strategy to develop self-sufficiency in radiopharmaceuticals, thus lowering costs and ensuring more consistent availability of treatment.
Furthermore, Jordan has positioned itself as a leader in nuclear research with its Jordan Research and Training Reactor (JRTR), which has been operational since 2016. This reactor plays a crucial role in producing medical isotopes used in diagnostic and therapeutic nuclear medicine. The JRTR not only strengthens Jordan’s domestic capabilities but also positions the country as a key player in the regional nuclear medicine landscape, exporting isotopes to other Middle Eastern countries. This development underscores the growing importance of nuclear medicine in the region and the ongoing efforts to enhance access to advanced healthcare solutions.
Middle East Nuclear Medicine Market Report Segmentation
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Middle East nuclear medicine market report based on product, application, end use, and country:Product Outlook (Revenue, USD Billion, 2021-2033)
- Diagnostics
- Therapeutics
Application Outlook (Revenue, USD Billion, 2021-2033)
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Pulmonary Scans
- Urology
- Other
End Use Outlook (Revenue, USD Billion, 2021-2033)
- Hospitals
- Diagnostic Centers
- Others
Country Outlook (Revenue, USD Million, 2021-2033)
- Middle East
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Middle East Nuclear Medicine Market Variables, Trends & Scope
Chapter 4. Middle East Nuclear Medicine Market: by Product Estimates & Trend Analysis
Chapter 5. Middle East Nuclear Medicine Market: Application Estimates & Trend Analysis
Chapter 6. Middle East Nuclear Medicine Market: End Use Estimates & Trend Analysis
Chapter 7. Middle East Nuclear Medicine Market: Regional Estimates & Trend Analysis by Product, Application, End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Middle East Nuclear Medicine market report include:- E Healthcare
- ubilant Life Sciences Ltd
- ordion (Canada), Inc.
- racco Imaging S.P.A
- he institute for radioelements (IRE)
- TP Radioisotopes SOC Ltd.
- he Australian Nuclear Science and Technology Organization
- czacıbaşı-Monrol
- antheus Medical Imaging, Inc
- ckert & Ziegler
- allinckrodt
- ardinal Health
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 375.4 Million |
| Forecasted Market Value ( USD | $ 727.3 Million |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 13 |
